By Mauro Orru

Novartis said new data from a late-phase trial showed that its Leqvio injection is effective at reducing cholesterol levels beyond six years in patients with atherosclerotic cardiovascular disease.

The Swiss pharmaceutical company said Monday that with twice-yearly dosing, Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol reduction.

Leqvio is approved in more than 80 countries, including the U.S.

Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94

(END) Dow Jones Newswires

August 28, 2023 08:50 ET (12:50 GMT)

Copyright (c) 2023 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024 Click aqui para mais gráficos Novartis.
Novartis (NYSE:NVS)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024 Click aqui para mais gráficos Novartis.